{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T21:00:13Z","timestamp":1793826013649,"version":"4.6.1"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,6,26]],"date-time":"2020-06-26T00:00:00Z","timestamp":1593129600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,26]],"date-time":"2020-06-26T00:00:00Z","timestamp":1593129600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100008349","name":"Universit\u00e4t Duisburg-Essen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100008349","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pathol. Oncol. Res."],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1007\/s12253-020-00834-y","type":"journal-article","created":{"date-parts":[[2020,6,27]],"date-time":"2020-06-27T03:01:02Z","timestamp":1593226862000},"page":"2523-2535","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["HDAC Inhibition Induces PD-L1 Expression in a Novel Anaplastic Thyroid Cancer Cell Line"],"prefix":"10.1007","volume":"26","author":[{"given":"Luca","family":"Heged\u0171s","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominika","family":"Rittler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tam\u00e1s","family":"Garay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Stockhammer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ildik\u00f3","family":"Kov\u00e1cs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bal\u00e1zs","family":"D\u00f6me","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Theurer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Hager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Herold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stavros","family":"Kalbourtzis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnes","family":"Bankfalvi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kurt W.","family":"Schmid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dagmar","family":"F\u00fchrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clemens","family":"Aigner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4341-4153","authenticated-orcid":false,"given":"Bal\u00e1zs","family":"Heged\u0171s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,26]]},"reference":[{"key":"834_CR1","doi-asserted-by":"publisher","first-page":"790834","DOI":"10.1155\/2014\/790834","volume":"2014","author":"M Ragazzi","year":"2014","unstructured":"Ragazzi M, Ciarrocchi A, Sancisi V, Gandolfi G, Bisagni A, Piana S (2014) Update on anaplastic thyroid carcinoma: morphological, molecular, and genetic features of the most aggressive thyroid cancer. Int J Endocrinol 2014:790834\u2013790813. \nhttps:\/\/doi.org\/10.1155\/2014\/790834","journal-title":"Int J Endocrinol"},{"key":"834_CR2","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.ejca.2017.02.023","volume":"77","author":"L Dal Maso","year":"2017","unstructured":"Dal Maso L, Tavilla A, Pacini F, Serraino D, BAC v D, Chirlaque MD, Capocaccia R, Larranaga N, Colonna M, Agius D, Ardanaz E, Rubio-Casadevall J, Kowalska A, Virdone S, Mallone S, Amash H, De Angelis R, Group E-W (2017) Survival of 86,690 patients with thyroid cancer: a population-based study in 29 European countries from EUROCARE-5. Eur J Cancer 77:140\u2013152. \nhttps:\/\/doi.org\/10.1016\/j.ejca.2017.02.023","journal-title":"Eur J Cancer"},{"key":"834_CR3","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1158\/1078-0432.CCR-18-0373","volume":"24","author":"N Pozdeyev","year":"2018","unstructured":"Pozdeyev N, Gay LM, Sokol ES, Hartmaier R, Deaver KE, Davis S, French JD, Borre PV, LaBarbera DV, Tan AC, Schweppe RE, Fishbein L, Ross JS, Haugen BR, Bowles DW (2018) Genetic analysis of 779 advanced differentiated and anaplastic thyroid cancers. Clin Cancer Res 24:3059\u20133068. \nhttps:\/\/doi.org\/10.1158\/1078-0432.CCR-18-0373","journal-title":"Clin Cancer Res"},{"issue":"3","key":"834_CR4","doi-asserted-by":"publisher","first-page":"234","DOI":"10.4132\/KoreanJPathol.2014.48.3.234","volume":"48","author":"JH Park","year":"2014","unstructured":"Park JH, Kwon HJ, Park CS, Hong S (2014) Anaplastic transformation of papillary thyroid carcinoma in a young man: a case study with Immunohistochemical and BRAF analysis. Korean J Pathol 48(3):234\u2013240. \nhttps:\/\/doi.org\/10.4132\/KoreanJPathol.2014.48.3.234","journal-title":"Korean J Pathol"},{"key":"834_CR5","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1186\/1752-1947-8-460","volume":"8","author":"T Abe","year":"2014","unstructured":"Abe T, Suzuki M, Shimizu K, Shinagawa N, Oizumi S, Matsuno Y, Miyazaki M, Tanino M, Tanaka S, Nishimura M (2014) Anaplastic transformation of papillary thyroid carcinoma in multiple lung metastases presenting with a malignant pleural effusion: a case report. J Med Case Rep 8:460. \nhttps:\/\/doi.org\/10.1186\/1752-1947-8-460","journal-title":"J Med Case Rep"},{"key":"834_CR6","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1158\/1535-7163.MCT-17-0871","volume":"17","author":"H Chen","year":"2018","unstructured":"Chen H, Luthra R, Routbort MJ, Patel KP, Cabanillas ME, Broaddus RR, Williams MD (2018) Molecular profile of advanced thyroid carcinomas by next-generation sequencing: characterizing tumors beyond diagnosis for targeted therapy. Mol Cancer Ther 17:1575\u20131584. \nhttps:\/\/doi.org\/10.1158\/1535-7163.MCT-17-0871","journal-title":"Mol Cancer Ther"},{"issue":"5","key":"834_CR7","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1089\/thy.2016.0254","volume":"27","author":"B Bonhomme","year":"2017","unstructured":"Bonhomme B, Godbert Y, Perot G, Al Ghuzlan A, Bardet S, Belleannee G, Criniere L, Do Cao C, Fouilloux G, Guyetant S, Kelly A, Leboulleux S, Buffet C, Leteurtre E, Michels JJ, Tissier F, Toubert ME, Wassef M, Pinard C, Hostein I, Soubeyran I (2017) Molecular pathology of anaplastic thyroid carcinomas: a retrospective study of 144 cases. Thyroid 27(5):682\u2013692. \nhttps:\/\/doi.org\/10.1089\/thy.2016.0254","journal-title":"Thyroid"},{"issue":"(26)","key":"834_CR8","doi-asserted-by":"publisher","first-page":"42613","DOI":"10.18632\/oncotarget.17300","volume":"8","author":"V Tiedje","year":"2017","unstructured":"Tiedje V, Ting S, Herold T, Synoracki S, Latteyer S, Moeller LC, Zwanziger D, Stuschke M, Fuehrer D, Schmid KW (2017) NGS based identification of mutational hotspots for targeted therapy in anaplastic thyroid carcinoma. Oncotarget 8((26)):42613\u201342620. \nhttps:\/\/doi.org\/10.18632\/oncotarget.17300","journal-title":"Oncotarget"},{"key":"834_CR9","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.1038\/ncomms3185","volume":"4","author":"J Vinagre","year":"2013","unstructured":"Vinagre J, Almeida A, Populo H, Batista R, Lyra J, Pinto V, Coelho R, Celestino R, Prazeres H, Lima L, Melo M, da Rocha AG, Preto A, Castro P, Castro L, Pardal F, Lopes JM, Santos LL, Reis RM, Cameselle-Teijeiro J, Sobrinho-Simoes M, Lima J, Maximo V, Soares P (2013) Frequency of TERT promoter mutations in human cancers. Nat Commun 4:2185. \nhttps:\/\/doi.org\/10.1038\/ncomms3185","journal-title":"Nat Commun"},{"issue":"1","key":"834_CR10","doi-asserted-by":"publisher","first-page":"44","DOI":"10.3978\/j.issn.2227-684X.2014.12.02","volume":"4","author":"XM Keutgen","year":"2015","unstructured":"Keutgen XM, Sadowski SM, Kebebew E (2015) Management of anaplastic thyroid cancer. Gland Surg 4(1):44\u201351. \nhttps:\/\/doi.org\/10.3978\/j.issn.2227-684X.2014.12.02","journal-title":"Gland Surg"},{"issue":"11","key":"834_CR11","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1038\/nrendo.2017.76","volume":"13","author":"E Molinaro","year":"2017","unstructured":"Molinaro E, Romei C, Biagini A, Sabini E, Agate L, Mazzeo S, Materazzi G, Sellari-Franceschini S, Ribechini A, Torregrossa L, Basolo F, Vitti P, Elisei R (2017) Anaplastic thyroid carcinoma: from clinicopathology to genetics and advanced therapies. Nat Rev Endocrinol 13(11):644\u2013660. \nhttps:\/\/doi.org\/10.1038\/nrendo.2017.76","journal-title":"Nat Rev Endocrinol"},{"issue":"1","key":"834_CR12","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1200\/JCO.2017.73.6785","volume":"36","author":"V Subbiah","year":"2018","unstructured":"Subbiah V, Kreitman RJ, Wainberg ZA, Cho JY, Schellens JHM, Soria JC, Wen PY, Zielinski C, Cabanillas ME, Urbanowitz G, Mookerjee B, Wang D, Rangwala F, Keam B (2018) Dabrafenib and Trametinib treatment in patients with locally advanced or metastatic BRAF V600-mutant anaplastic thyroid Cancer. J Clin Oncol 36(1):7\u201313. \nhttps:\/\/doi.org\/10.1200\/JCO.2017.73.6785","journal-title":"J Clin Oncol"},{"issue":"6","key":"834_CR13","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1210\/jc.2016-3756","volume":"102","author":"AV Chintakuntlawar","year":"2017","unstructured":"Chintakuntlawar AV, Rumilla KM, Smith CY, Jenkins SM, Foote RL, Kasperbauer JL, Morris JC, Ryder M, Alsidawi S, Hilger C, Bible KC (2017) Expression of PD-1 and PD-L1 in anaplastic thyroid Cancer patients treated with multimodal therapy: results from a retrospective study. J Clin Endocrinol Metab 102(6):1943\u20131950. \nhttps:\/\/doi.org\/10.1210\/jc.2016-3756","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"834_CR14","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1634\/theoncologist.2017-0096","volume":"22","author":"R Kollipara","year":"2017","unstructured":"Kollipara R, Schneider B, Radovich M, Babu S, Kiel PJ (2017) Exceptional response with immunotherapy in a patient with anaplastic thyroid Cancer. Oncologist 22(10):1149\u20131151. \nhttps:\/\/doi.org\/10.1634\/theoncologist.2017-0096","journal-title":"Oncologist"},{"issue":"1","key":"834_CR15","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1007\/s12020-019-01865-5","volume":"64","author":"S Cantara","year":"2019","unstructured":"Cantara S, Bertelli E, Occhini R, Regoli M, Brilli L, Pacini F, Castagna MG, Toti P (2019) Blockade of the programmed death ligand 1 (PD-L1) as potential therapy for anaplastic thyroid cancer. Endocrine 64(1):122\u2013129. \nhttps:\/\/doi.org\/10.1007\/s12020-019-01865-5","journal-title":"Endocrine"},{"issue":"10","key":"834_CR16","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1038\/s41416-018-0296-2","volume":"119","author":"V Gunda","year":"2018","unstructured":"Gunda V, Gigliotti B, Ndishabandi D, Ashry T, McCarthy M, Zhou Z, Amin S, Freeman GJ, Alessandrini A, Parangi S (2018) Combinations of BRAF inhibitor and anti-PD-1\/PD-L1 antibody improve survival and tumour immunity in an immunocompetent model of orthotopic murine anaplastic thyroid cancer. Br J Cancer 119(10):1223\u20131232. \nhttps:\/\/doi.org\/10.1038\/s41416-018-0296-2","journal-title":"Br J Cancer"},{"issue":"7","key":"834_CR17","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1089\/thy.2018.0060","volume":"28","author":"ME Cabanillas","year":"2018","unstructured":"Cabanillas ME, Ferrarotto R, Garden AS, Ahmed S, Busaidy NL, Dadu R, Williams MD, Skinner H, Gunn GB, Grosu H, Iyer P, Hofmann MC, Zafereo M (2018) Neoadjuvant BRAF- and immune-directed therapy for anaplastic thyroid carcinoma. Thyroid 28(7):945\u2013951. \nhttps:\/\/doi.org\/10.1089\/thy.2018.0060","journal-title":"Thyroid"},{"issue":"1","key":"834_CR18","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s40425-018-0378-y","volume":"6","author":"PC Iyer","year":"2018","unstructured":"Iyer PC, Dadu R, Gule-Monroe M, Busaidy NL, Ferrarotto R, Habra MA, Zafereo M, Williams MD, Gunn GB, Grosu H, Skinner HD, Sturgis EM, Gross N, Cabanillas ME (2018) Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma. J Immunother Cancer 6(1):68. \nhttps:\/\/doi.org\/10.1186\/s40425-018-0378-y","journal-title":"J Immunother Cancer"},{"issue":"10","key":"834_CR19","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1634\/theoncologist.12-10-1247","volume":"12","author":"BS Mann","year":"2007","unstructured":"Mann BS, Johnson JR, Cohen MH, Justice R, Pazdur R (2007) FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist 12(10):1247\u20131252. \nhttps:\/\/doi.org\/10.1634\/theoncologist.12-10-1247","journal-title":"Oncologist"},{"issue":"1","key":"834_CR20","doi-asserted-by":"publisher","first-page":"19","DOI":"10.7150\/jca.16655","volume":"8","author":"A Grabarska","year":"2017","unstructured":"Grabarska A, Luszczki JJ, Nowosadzka E, Gumbarewicz E, Jeleniewicz W, Dmoszynska-Graniczka M, Kowalczuk K, Kupisz K, Polberg K, Stepulak A (2017) Histone Deacetylase inhibitor SAHA as potential targeted therapy agent for larynx Cancer cells. J Cancer 8(1):19\u201328. \nhttps:\/\/doi.org\/10.7150\/jca.16655","journal-title":"J Cancer"},{"issue":"7","key":"834_CR21","doi-asserted-by":"publisher","first-page":"5051","DOI":"10.1007\/s13277-015-3156-1","volume":"36","author":"B Yang","year":"2015","unstructured":"Yang B, Yu D, Liu J, Yang K, Wu G, Liu H (2015) Antitumor activity of SAHA, a novel histone deacetylase inhibitor, against murine B cell lymphoma A20 cells in vitro and in vivo. Tumour Biol 36(7):5051\u20135061. \nhttps:\/\/doi.org\/10.1007\/s13277-015-3156-1","journal-title":"Tumour Biol"},{"issue":"4","key":"834_CR22","doi-asserted-by":"publisher","first-page":"419","DOI":"10.4103\/0019-5154.160511","volume":"60","author":"AK Bubna","year":"2015","unstructured":"Bubna AK (2015) Vorinostat-An overview. Vorinostat-An Overview Indian J Dermatol 60(4):419. \nhttps:\/\/doi.org\/10.4103\/0019-5154.160511","journal-title":"Vorinostat-An Overview Indian J Dermatol"},{"issue":"Suppl 1","key":"834_CR23","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1038\/sj.bjc.6603463","volume":"95","author":"VM Richon","year":"2006","unstructured":"Richon VM (2006) Cancer biology: mechanism of antitumour action of vorinostat (suberoylanilide hydroxamic acid), a novel histone deacetylase inhibitor. Br J Cancer 95(Suppl 1):S2\u2013S6. \nhttps:\/\/doi.org\/10.1038\/sj.bjc.6603463","journal-title":"Br J Cancer"},{"issue":"3","key":"834_CR24","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.ctrv.2007.11.003","volume":"34","author":"A Duenas-Gonzalez","year":"2008","unstructured":"Duenas-Gonzalez A, Candelaria M, Perez-Plascencia C, Perez-Cardenas E, de la Cruz-Hernandez E, Herrera LA (2008) Valproic acid as epigenetic cancer drug: preclinical, clinical and transcriptional effects on solid tumors. Cancer Treat Rev 34(3):206\u2013222. \nhttps:\/\/doi.org\/10.1016\/j.ctrv.2007.11.003","journal-title":"Cancer Treat Rev"},{"issue":"2","key":"834_CR25","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1038\/sj.bjc.6603851","volume":"97","author":"A Atmaca","year":"2007","unstructured":"Atmaca A, Al-Batran SE, Maurer A, Neumann A, Heinzel T, Hentsch B, Schwarz SE, Hovelmann S, Gottlicher M, Knuth A, Jager E (2007) Valproic acid (VPA) in patients with refractory advanced cancer: a dose escalating phase I clinical trial. Br J Cancer 97(2):177\u2013182. \nhttps:\/\/doi.org\/10.1038\/sj.bjc.6603851","journal-title":"Br J Cancer"},{"issue":"10","key":"834_CR26","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1586\/14737140.2014.940329","volume":"14","author":"SA Brodie","year":"2014","unstructured":"Brodie SA, Brandes JC (2014) Could valproic acid be an effective anticancer agent? The evidence so far. Expert Rev Anticanc 14(10):1097\u20131100. \nhttps:\/\/doi.org\/10.1586\/14737140.2014.940329","journal-title":"Expert Rev Anticanc"},{"issue":"2","key":"834_CR27","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1677\/joe.1.06970","volume":"191","author":"MG Catalano","year":"2006","unstructured":"Catalano MG, Fortunati N, Pugliese M, Poli R, Bosco O, Mastrocola R, Aragno M, Boccuzzi G (2006) Valproic acid, a histone deacetylase inhibitor, enhances sensitivity to doxorubicin in anaplastic thyroid cancer cells. J Endocrinol 191(2):465\u2013472. \nhttps:\/\/doi.org\/10.1677\/joe.1.06970","journal-title":"J Endocrinol"},{"issue":"2","key":"834_CR28","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1507\/endocrj.K08E-016","volume":"56","author":"H Noguchi","year":"2009","unstructured":"Noguchi H, Yamashita H, Murakami T, Hirai K, Noguchi Y, Maruta J, Yokoi T, Noguchi S (2009) Successful treatment of anaplastic thyroid carcinoma with a combination of oral valproic acid, chemotherapy, radiation and surgery. Endocr J 56(2):245\u2013249","journal-title":"Endocr J"},{"key":"834_CR29","doi-asserted-by":"publisher","first-page":"2930414","DOI":"10.1155\/2016\/2930414","volume":"2016","author":"MG Catalano","year":"2016","unstructured":"Catalano MG, Pugliese M, Gallo M, Brignardello E, Milla P, Orlandi F, Limone PP, Arvat E, Boccuzzi G, Piovesan A (2016) Valproic acid, a histone Deacetylase inhibitor, in combination with paclitaxel for anaplastic thyroid Cancer: results of a multicenter randomized controlled phase II\/III trial. Int J Endocrinol 2016:2930414\u20132930418. \nhttps:\/\/doi.org\/10.1155\/2016\/2930414","journal-title":"Int J Endocrinol"},{"issue":"3","key":"834_CR30","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1002\/ijc.26057","volume":"130","author":"MG Catalano","year":"2012","unstructured":"Catalano MG, Pugliese M, Gargantini E, Grange C, Bussolati B, Asioli S, Bosco O, Poli R, Compagnone A, Bandino A, Mainini F, Fortunati N, Boccuzzi G (2012) Cytotoxic activity of the histone deacetylase inhibitor panobinostat (LBH589) in anaplastic thyroid cancer in vitro and in vivo. Int J Cancer 130(3):694\u2013704. \nhttps:\/\/doi.org\/10.1002\/ijc.26057","journal-title":"Int J Cancer"},{"key":"834_CR31","doi-asserted-by":"publisher","unstructured":"Lin CL, Tsai ML, Lin CY, Hsu KW, Hsieh WS, Chi WM, Huang LC, Lee CH (2019) HDAC1 and HDAC2 double knockout triggers cell apoptosis in advanced thyroid Cancer. Int J Mol Sci 20(2). \nhttps:\/\/doi.org\/10.3390\/ijms20020454","DOI":"10.3390\/ijms20020454"},{"issue":"6","key":"834_CR32","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1089\/thy.2012.0252","volume":"23","author":"N Besic","year":"2013","unstructured":"Besic N, Gazic B (2013) Sites of metastases of anaplastic thyroid carcinoma: autopsy findings in 45 cases from a single institution. Thyroid 23(6):709\u2013713. \nhttps:\/\/doi.org\/10.1089\/thy.2012.0252","journal-title":"Thyroid"},{"key":"834_CR33","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.mce.2017.03.007","volume":"448","author":"V Maggisano","year":"2017","unstructured":"Maggisano V, Celano M, Lombardo GE, Lepore SM, Sponziello M, Rosignolo F, Verrienti A, Baldan F, Puxeddu E, Durante C, Filetti S, Damante G, Russo D, Bulotta S (2017) Silencing of hTERT blocks growth and migration of anaplastic thyroid cancer cells. Mol Cell Endocrinol 448:34\u201340. \nhttps:\/\/doi.org\/10.1016\/j.mce.2017.03.007","journal-title":"Mol Cell Endocrinol"},{"issue":"(11)","key":"834_CR34","doi-asserted-by":"publisher","first-page":"9073","DOI":"10.18632\/oncotarget.3268","volume":"6","author":"L Zhang","year":"2015","unstructured":"Zhang L, Zhang Y, Mehta A, Boufraqech M, Davis S, Wang J, Tian Z, Yu Z, Boxer MB, Kiefer JA, Copland JA, Smallridge RC, Li Z, Shen M, Kebebew E (2015) Dual inhibition of HDAC and EGFR signaling with CUDC-101 induces potent suppression of tumor growth and metastasis in anaplastic thyroid cancer. Oncotarget 6((11)):9073\u20139085. \nhttps:\/\/doi.org\/10.18632\/oncotarget.3268","journal-title":"Oncotarget"},{"issue":"4","key":"834_CR35","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1158\/1535-7163.MCT-04-0293","volume":"4","author":"S Kim","year":"2005","unstructured":"Kim S, Schiff BA, Yigitbasi OG, Doan D, Jasser SA, Bekele BN, Mandal M, Myers JN (2005) Targeted molecular therapy of anaplastic thyroid carcinoma with AEE788. Mol Cancer Ther 4(4):632\u2013640. \nhttps:\/\/doi.org\/10.1158\/1535-7163.MCT-04-0293","journal-title":"Mol Cancer Ther"},{"issue":"20","key":"834_CR36","doi-asserted-by":"publisher","first-page":"3094","DOI":"10.1016\/j.yexcr.2013.08.018","volume":"319","author":"T Garay","year":"2013","unstructured":"Garay T, Juh\u00e1sz \u00c9, Moln\u00e1r E, Eisenbauer M, Czir\u00f3k A, Dekan B, L\u00e1szl\u00f3 V, Hoda MA, D\u00f6me B, T\u00edm\u00e1r J, Klepetko W, Berger W, Heged\u0171s B (2013) Cell migration or cytokinesis and proliferation?--revisiting the \"go or grow\" hypothesis in cancer cells in vitro. Exp Cell Res 319(20):3094\u20133103. \nhttps:\/\/doi.org\/10.1016\/j.yexcr.2013.08.018","journal-title":"Exp Cell Res"},{"issue":"2","key":"834_CR37","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","volume":"70","author":"TC Chou","year":"2010","unstructured":"Chou TC (2010) Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 70(2):440\u2013446. \nhttps:\/\/doi.org\/10.1158\/0008-5472.CAN-09-1947","journal-title":"Cancer Res"},{"issue":"12","key":"834_CR38","doi-asserted-by":"publisher","first-page":"2758","DOI":"10.1002\/ijc.30503","volume":"140","author":"L Hegedus","year":"2017","unstructured":"Hegedus L, Garay T, Molnar E, Varga K, Bilecz A, Torok S, Padanyi R, Paszty K, Wolf M, Grusch M, Kallay E, Dome B, Berger W, Hegedus B, Enyedi A (2017) The plasma membrane Ca(2+) pump PMCA4b inhibits the migratory and metastatic activity of BRAF mutant melanoma cells. Int J Cancer 140(12):2758\u20132770. \nhttps:\/\/doi.org\/10.1002\/ijc.30503","journal-title":"Int J Cancer"},{"issue":"7","key":"834_CR39","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1093\/annonc\/mdx176","volume":"28","author":"GV Long","year":"2017","unstructured":"Long GV, Flaherty KT, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, Garbe C, Jouary T, Hauschild A, Chiarion-Sileni V, Lebbe C, Mandala M, Millward M, Arance A, Bondarenko I, Haanen J, Hansson J, Utikal J, Ferraresi V, Mohr P, Probachai V, Schadendorf D, Nathan P, Robert C, Ribas A, Davies MA, Lane SR, Legos JJ, Mookerjee B, Grob JJ (2017) Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E\/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study. Ann Oncol 28(7):1631\u20131639. \nhttps:\/\/doi.org\/10.1093\/annonc\/mdx176","journal-title":"Ann Oncol"},{"issue":"3","key":"834_CR40","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1089\/105072503321582042","volume":"13","author":"J Kurebayashi","year":"2003","unstructured":"Kurebayashi J, Otsuki T, Tanaka K, Yamamoto Y, Moriya T, Sonoo H (2003) Medroxyprogesterone acetate decreases secretion of interleukin-6 and parathyroid hormone-related protein in a new anaplastic thyroid cancer cell line, KTC-2. Thyroid 13(3):249\u2013258. \nhttps:\/\/doi.org\/10.1089\/105072503321582042","journal-title":"Thyroid"},{"issue":"12","key":"834_CR41","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1089\/thy.2009.0195","volume":"19","author":"T Pilli","year":"2009","unstructured":"Pilli T, Prasad KV, Jayarama S, Pacini F, Prabhakar BS (2009) Potential utility and limitations of thyroid cancer cell lines as models for studying thyroid cancer. Thyroid 19(12):1333\u20131342. \nhttps:\/\/doi.org\/10.1089\/thy.2009.0195","journal-title":"Thyroid"},{"issue":"11","key":"834_CR42","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1038\/modpathol.2017.75","volume":"30","author":"N Oishi","year":"2017","unstructured":"Oishi N, Kondo T, Ebina A, Sato Y, Akaishi J, Hino R, Yamamoto N, Mochizuki K, Nakazawa T, Yokomichi H, Ito K, Ishikawa Y, Katoh R (2017) Molecular alterations of coexisting thyroid papillary carcinoma and anaplastic carcinoma: identification of TERT mutation as an independent risk factor for transformation. Mod Pathol 30(11):1527\u20131537. \nhttps:\/\/doi.org\/10.1038\/modpathol.2017.75","journal-title":"Mod Pathol"},{"issue":"7","key":"834_CR43","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1053\/ejso.2001.1203","volume":"27","author":"KY Lam","year":"2001","unstructured":"Lam KY, Lui MC, Lo CY (2001) Cytokeratin expression profiles in thyroid carcinomas. Eur J Surg Oncol 27(7):631\u2013635. \nhttps:\/\/doi.org\/10.1053\/ejso.2001.1203","journal-title":"Eur J Surg Oncol"},{"issue":"2","key":"834_CR44","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1038\/modpathol.3801002","volume":"21","author":"D Nonaka","year":"2008","unstructured":"Nonaka D, Tang Y, Chiriboga L, Rivera M, Ghossein R (2008) Diagnostic utility of thyroid transcription factors Pax8 and TTF-2 (FoxE1) in thyroid epithelial neoplasms. Mod Pathol 21(2):192\u2013200. \nhttps:\/\/doi.org\/10.1038\/modpathol.3801002","journal-title":"Mod Pathol"},{"key":"834_CR45","doi-asserted-by":"publisher","first-page":"133","DOI":"10.3389\/fendo.2012.00133","volume":"3","author":"M Saiselet","year":"2012","unstructured":"Saiselet M, Floor S, Tarabichi M, Dom G, Hebrant A, van Staveren WC, Maenhaut C (2012) Thyroid cancer cell lines: an overview. Front Endocrinol (Lausanne) 3:133. \nhttps:\/\/doi.org\/10.3389\/fendo.2012.00133","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"47","key":"834_CR46","doi-asserted-by":"publisher","first-page":"5397","DOI":"10.1038\/onc.2013.544","volume":"33","author":"ZA Antonello","year":"2014","unstructured":"Antonello ZA, Nucera C (2014) Orthotopic mouse models for the preclinical and translational study of targeted therapies against metastatic human thyroid carcinoma with BRAF(V600E) or wild-type BRAF. Oncogene 33(47):5397\u20135404. \nhttps:\/\/doi.org\/10.1038\/onc.2013.544","journal-title":"Oncogene"},{"issue":"16","key":"834_CR47","doi-asserted-by":"publisher","first-page":"E1600","DOI":"10.1073\/pnas.1404357111","volume":"111","author":"DG McFadden","year":"2014","unstructured":"McFadden DG, Vernon A, Santiago PM, Martinez-McFaline R, Bhutkar A, Crowley DM, McMahon M, Sadow PM, Jacks T (2014) p53 constrains progression to anaplastic thyroid carcinoma in a Braf-mutant mouse model of papillary thyroid cancer. Proc Natl Acad Sci U S A 111(16):E1600\u2013E1609. \nhttps:\/\/doi.org\/10.1073\/pnas.1404357111","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"23","key":"834_CR48","doi-asserted-by":"publisher","first-page":"10649","DOI":"10.1073\/pnas.1004934107","volume":"107","author":"C Nucera","year":"2010","unstructured":"Nucera C, Porrello A, Antonello ZA, Mekel M, Nehs MA, Giordano TJ, Gerald D, Benjamin LE, Priolo C, Puxeddu E, Finn S, Jarzab B, Hodin RA, Pontecorvi A, Nose V, Lawler J, Parangi S (2010) B-Raf(V600E) and thrombospondin-1 promote thyroid cancer progression. Proc Natl Acad Sci U S A 107(23):10649\u201310654. \nhttps:\/\/doi.org\/10.1073\/pnas.1004934107","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"834_CR49","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1210\/en.2011-1519","volume":"153","author":"MA Nehs","year":"2012","unstructured":"Nehs MA, Nucera C, Nagarkatti SS, Sadow PM, Morales-Garcia D, Hodin RA, Parangi S (2012) Late intervention with anti-BRAF(V600E) therapy induces tumor regression in an orthotopic mouse model of human anaplastic thyroid cancer. Endocrinology 153(2):985\u2013994. \nhttps:\/\/doi.org\/10.1210\/en.2011-1519","journal-title":"Endocrinology"},{"issue":"10","key":"834_CR50","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1002\/ijc.31225","volume":"142","author":"R Bu","year":"2018","unstructured":"Bu R, Siraj AK, Divya SP, Kong Y, Parvathareddy SK, Al-Rasheed M, Al-Obaisi KAS, Victoria IG, Al-Sobhi SS, Al-Dawish M, Al-Dayel F, Al-Kuraya KS (2018) Telomerase reverse transcriptase mutations are independent predictor of disease-free survival in middle eastern papillary thyroid cancer. Int J Cancer 142(10):2028\u20132039. \nhttps:\/\/doi.org\/10.1002\/ijc.31225","journal-title":"Int J Cancer"},{"issue":"2","key":"834_CR51","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1111\/cen.12999","volume":"85","author":"M Bullock","year":"2016","unstructured":"Bullock M, Ren Y, O'Neill C, Gill A, Aniss A, Sywak M, Sidhu S, Delbridge L, Learoyd D, de Vathaire F, Robinson BG, Clifton-Bligh RJ (2016) TERT promoter mutations are a major indicator of recurrence and death due to papillary thyroid carcinomas. Clin Endocrinol 85(2):283\u2013290. \nhttps:\/\/doi.org\/10.1111\/cen.12999","journal-title":"Clin Endocrinol"},{"issue":"10","key":"834_CR52","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0076340","volume":"8","author":"HW Chiu","year":"2013","unstructured":"Chiu HW, Yeh YL, Wang YC, Huang WJ, Chen YA, Chiou YS, Ho SY, Lin P, Wang YJ (2013) Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, enhances radiosensitivity and suppresses lung metastasis in breast cancer in vitro and in vivo. PLoS One 8(10):e76340. \nhttps:\/\/doi.org\/10.1371\/journal.pone.0076340","journal-title":"PLoS One"},{"key":"834_CR53","doi-asserted-by":"publisher","first-page":"95","DOI":"10.3389\/fonc.2017.00095","volume":"7","author":"L Hegedus","year":"2017","unstructured":"Hegedus L, Padanyi R, Molnar J, Paszty K, Varga K, Kenessey I, Sarkozy E, Wolf M, Grusch M, Hegyi Z, Homolya L, Aigner C, Garay T, Hegedus B, Timar J, Kallay E, Enyedi A (2017) Histone Deacetylase inhibitor treatment increases the expression of the plasma membrane Ca(2+) pump PMCA4b and inhibits the migration of melanoma cells independent of ERK. Front Oncol 7:95. \nhttps:\/\/doi.org\/10.3389\/fonc.2017.00095","journal-title":"Front Oncol"},{"issue":"4","key":"834_CR54","doi-asserted-by":"publisher","first-page":"641","DOI":"10.2217\/epi.15.16","volume":"7","author":"J Park","year":"2015","unstructured":"Park J, Thomas S, Munster PN (2015) Epigenetic modulation with histone deacetylase inhibitors in combination with immunotherapy. Epigenomics 7(4):641\u2013652. \nhttps:\/\/doi.org\/10.2217\/epi.15.16","journal-title":"Epigenomics"},{"issue":"(69)","key":"834_CR55","doi-asserted-by":"publisher","first-page":"114156","DOI":"10.18632\/oncotarget.23169","volume":"8","author":"M Terranova-Barberio","year":"2017","unstructured":"Terranova-Barberio M, Thomas S, Ali N, Pawlowska N, Park J, Krings G, Rosenblum MD, Budillon A, Munster PN (2017) HDAC inhibition potentiates immunotherapy in triple negative breast cancer. Oncotarget 8((69)):114156\u2013114172. \nhttps:\/\/doi.org\/10.18632\/oncotarget.23169","journal-title":"Oncotarget"},{"issue":"12","key":"834_CR56","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1158\/2326-6066.CIR-15-0077-T","volume":"3","author":"DM Woods","year":"2015","unstructured":"Woods DM, Sodre AL, Villagra A, Sarnaik A, Sotomayor EM, Weber J (2015) HDAC inhibition Upregulates PD-1 ligands in melanoma and augments immunotherapy with PD-1 blockade. Cancer Immunol Res 3(12):1375\u20131385. \nhttps:\/\/doi.org\/10.1158\/2326-6066.CIR-15-0077-T","journal-title":"Cancer Immunol Res"},{"key":"834_CR57","doi-asserted-by":"publisher","unstructured":"Booth L, Roberts JL, Poklepovic A, Kirkwood J, Dent P (2017) HDAC inhibitors enhance the immunotherapy response of melanoma cells. Oncotarget 8 (47):83155-83170. \nhttps:\/\/doi.org\/10.18632\/oncotarget.17950","DOI":"10.18632\/oncotarget.17950"},{"issue":"7","key":"834_CR58","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1210\/jc.2015-4227","volume":"101","author":"JJ Bastman","year":"2016","unstructured":"Bastman JJ, Serracino HS, Zhu Y, Koenig MR, Mateescu V, Sams SB, Davies KD, Raeburn CD, McIntyre RC Jr, Haugen BR, French JD (2016) Tumor-infiltrating T cells and the PD-1 checkpoint pathway in advanced differentiated and anaplastic thyroid Cancer. J Clin Endocrinol Metab 101(7):2863\u20132873. \nhttps:\/\/doi.org\/10.1210\/jc.2015-4227","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"834_CR59","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1001\/jamaoncol.2018.1701","volume":"4","author":"AM Goodman","year":"2018","unstructured":"Goodman AM, Piccioni D, Kato S, Boichard A, Wang HY, Frampton G, Lippman SM, Connelly C, Fabrizio D, Miller V, Sicklick JK, Kurzrock R (2018) Prevalence of PDL1 amplification and preliminary response to immune checkpoint blockade in solid tumors. JAMA Oncol 4(9):1237\u20131244. \nhttps:\/\/doi.org\/10.1001\/jamaoncol.2018.1701","journal-title":"JAMA Oncol"},{"issue":"3","key":"834_CR60","first-page":"974","volume":"12","author":"M Ma","year":"2020","unstructured":"Ma M, Lin B, Wang M, Liang X, Su L, Okose O, Lv W, Li J (2020) Immunotherapy in anaplastic thyroid cancer. Am J Transl Res 12(3):974\u2013988","journal-title":"Am J Transl Res"},{"issue":"(13)","key":"834_CR61","doi-asserted-by":"publisher","first-page":"17194","DOI":"10.18632\/oncotarget.7839","volume":"7","author":"E Brauner","year":"2016","unstructured":"Brauner E, Gunda V, Vanden Borre P, Zurakowski D, Kim YS, Dennett KV, Amin S, Freeman GJ, Parangi S (2016) Combining BRAF inhibitor and anti PD-L1 antibody dramatically improves tumor regression and anti tumor immunity in an immunocompetent murine model of anaplastic thyroid cancer. Oncotarget 7((13)):17194\u201317211. \nhttps:\/\/doi.org\/10.18632\/oncotarget.7839","journal-title":"Oncotarget"},{"key":"834_CR62","doi-asserted-by":"publisher","unstructured":"Cabanillas M, Busaidy N, Dadu R, Ferrarotto R, Gross N, Gule-Monroe M, Lu C, Grosu H, Williams M, Zafereo M (2019) OR27-6 combination Vemurafenib (BRAF inhibitor)\/Cobimetinib (MEK inhibitor)\/Atezolizumab (anti-PDL1 inhibitor) in BRAF-V600E mutated anaplastic thyroid Cancer (ATC): initial safety and feasibility. Journal of the Endocrine Society 3((Supplement_1)). \nhttps:\/\/doi.org\/10.1210\/js.2019-OR27-6","DOI":"10.1210\/js.2019-OR27-6"},{"issue":"3","key":"834_CR63","doi-asserted-by":"publisher","first-page":"150","DOI":"10.5306\/wjco.v2.i3.150","volume":"2","author":"F Perri","year":"2011","unstructured":"Perri F, Lorenzo GD, Scarpati GD, Buonerba C (2011) Anaplastic thyroid carcinoma: a comprehensive review of current and future therapeutic options. World J Clin Oncol 2(3):150\u2013157. \nhttps:\/\/doi.org\/10.5306\/wjco.v2.i3.150","journal-title":"World J Clin Oncol"},{"issue":"9","key":"834_CR64","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s00432-005-0673-0","volume":"131","author":"W Voigt","year":"2005","unstructured":"Voigt W, Kegel T, Weiss M, Mueller T, Simon H, Schmoll HJ (2005) Potential activity of paclitaxel, vinorelbine and gemcitabine in anaplastic thyroid carcinoma. J Cancer Res Clin Oncol 131(9):585\u2013590. \nhttps:\/\/doi.org\/10.1007\/s00432-005-0673-0","journal-title":"J Cancer Res Clin Oncol"},{"issue":"3","key":"834_CR65","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1677\/ERC-07-0096","volume":"14","author":"MG Catalano","year":"2007","unstructured":"Catalano MG, Poli R, Pugliese M, Fortunati N, Boccuzzi G (2007) Valproic acid enhances tubulin acetylation and apoptotic activity of paclitaxel on anaplastic thyroid cancer cell lines. Endocr Relat Cancer 14(3):839\u2013845. \nhttps:\/\/doi.org\/10.1677\/ERC-07-0096","journal-title":"Endocr Relat Cancer"}],"container-title":["Pathology & Oncology Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12253-020-00834-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12253-020-00834-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12253-020-00834-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,3]],"date-time":"2020-09-03T14:23:07Z","timestamp":1599142987000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12253-020-00834-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,26]]},"references-count":65,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["834"],"URL":"https:\/\/doi.org\/10.1007\/s12253-020-00834-y","relation":{},"ISSN":["1219-4956","1532-2807"],"issn-type":[{"value":"1219-4956","type":"print"},{"value":"1532-2807","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,26]]},"assertion":[{"value":"6 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The cell line establishment study was approved by the Ethic Committee of the University Duisburg-Essen (#18\u20138208-BO) and the patient provided informed consent. The study was carried out in accordance with the Declaration of Helsinki. The animal model protocol was carried out in accordance with the Guidelines for Animal Experiments and was approved for the National Institute of Oncology, Budapest, Hungary (PEI\/001\/2574\u20136\/2015).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval and Consent to Participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The authors declare that they have no competing interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interests"}}]}}